RSVA405

RSVA405 is a potent, orally active activator of AMPK, with an EC50 of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 can also be used for the research of obesity[1][2][3][4].

Product Specifications

CAS Number

[140405-36-3]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

AMPK; Autophagy; STAT

Type

Reference compound

Related Pathways

Autophagy; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/rsva405.html

Purity

99.72

Solubility

DMSO : 116.67 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=NC=C1)N/N=C/C2=CC=C(N(CC)CC)C=C2O

Molecular Formula

C17H20N4O2

Molecular Weight

312.37

Precautions

H302, H312, H332

References & Citations

[1]Khader A, et, al. Novel resveratrol analogues attenuate renal ischemic injury in rats. J Surg Res. 2015 Feb;193 (2) :807-15.|[2]Vingtdeux V, et, al. Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med. Sep-Oct 2011;17 (9-10) :1022-30.|[3]Capiralla H, et, al. Identification of potent small-molecule inhibitors of STAT3 with anti-inflammatory properties in RAW 264.7 macrophages. FEBS J. 2012 Oct;279 (20) :3791-9.|[4]Vingtdeux V, et, al. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J. 2011 Jan;25 (1) :219-31.